Video

Optimizing Radiation Therapy in Hodgkin Lymphoma

For High-Definition, Click

Long-term side effects are the leading concern when administering radiation therapy in early-stage Hodgkin lymphoma. However, these side effects often do not manifest for 10 to 20 years following treatment, which complicates studies examining optimal treatment approaches. As a result, Jonathan W. Friedberg, MD, believes that long-term follow-up from trials examining first-line treatment approaches will be more revealing than shorter analyses.

The standard approach for administering radiation has evolved significantly from extended-field radiation to the current standard of involved-field radiation, Craig H. Moskowitz, MD says. This new approach applies radiation only to the affected lymph node, which has been shown to be equally effective and less toxic than extended-field radiation. Longer follow up is still pending to ascertain if these approaches reduce the occurrence of long-term side effects.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

May 15th 2025 - May 16th 2026

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer
Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

May 15th 2025 - May 16th 2026

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

May 14th 2025 - Jun 19th 2025

online-activity